603 POSTER Effect of the SRC tyrosine kinase inhibitor dasatinib in combination with erlotinib and in cells with acquired resistance to erlotinib

E.Haura; J.Gao; J.Li

首页> 外文期刊>European Journal of Cancer Supplements >603 POSTER Effect of the SRC tyrosine kinase inhibitor dasatinib in combination with erlotinib and in cells with acquired resistance to erlotinib

【24h】

603 POSTER Effect of the SRC tyrosine kinase inhibitor dasatinib in combination with erlotinib and in cells with acquired resistance to erlotinib

机译：603 POSTER SRC酪氨酸激酶抑制剂达沙替尼与厄洛替尼联合使用以及在对厄洛替尼具有获得性耐药的细胞中的作用

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第12期|共1页
作者
E.Haura; J.Gao; J.Li;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. [J] . Johnson ML, Riely GJ, Rizvi NA, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2011,第6期

机译：达沙替尼II期试验用于表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼或吉非替尼治疗获得性耐药的患者。
2. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. [J] . Nakachi I, Naoki K, Soejima K, Molecular cancer research: MCR . 2010,第8期

机译：多受体酪氨酸激酶抑制剂和雷帕霉素抑制剂的哺乳动物靶点的组合通过c-Met抑制作用克服了肺癌细胞系中的厄洛替尼耐药性。
3. Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors [J] . GoldbergS.B., OxnardG.R., DigumarthyS., The oncologist . 2013,第11期

机译：对EGFR酪氨酸激酶抑制剂有抗药性的晚期非小细胞肺癌单独使用厄洛替尼进行化学疗法或化学疗法
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Design synthesis and biological evaluation of bioisosteric analogues of dasatinib as Src, Abl and Abl T3151 protein tyrosine kinase inhibitors [D] . Patel, Jay P. 2013

机译：dasatinib作为Src，Abl和Abl T3151蛋白酪氨酸激酶抑制剂的生物立体异构体的设计合成和生物学评估
6. Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib [O] . Melissa L. Johnson, Greg J. Riely, Naiyer A. Rizvi, -1

机译：达沙替尼的II期临床试验与获得性耐药患者治疗表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼或吉非替尼
7. Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib [O] . Johnson Melissa L., Riely Greg J., Rizvi Naiyer A., 2011

机译：达沙替尼用于表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼或吉非替尼治疗获得性耐药的II期临床试验

603 POSTER Effect of the SRC tyrosine kinase inhibitor dasatinib in combination with erlotinib and in cells with acquired resistance to erlotinib

著录项

相似文献

相关主题

期刊订阅